Table 2.
Vehicle (n = 20) | MK-0626 (n = 13) | Pioglitazone (n = 12) | Alendronate (n = 7) | |
---|---|---|---|---|
BV/TV (%) | 7.16 ± 1.7 | 6.58 ± 1.60 | 8.7 ± 1.64 | 10.79 ± 1.07 * |
Tb.Th, μm | 0.043 ± 0.002 | 0.044 ± 0.002 | 0.044 ± 0.000 | 0.041 ± 0.001 |
Tb.N/mm | 1.64 ± 0.379 | 1.45 ± 0.32 | 1.96 ± 0.34 | 2.59 ± 0.26 * |
Tb.Sp, μm | 0.25 ± 0.034 | 0.28 ± 0.027 | 0.24 ± 0.015 | 0.19 ± 0.014* |
BV/TV, %, bone volume per total volume; Tb.Th, μm, trabecular thickness; Tb.N, mm−1, trabecular number; Tb.Sp, μm, trabecular separation. Results are expressed as mean values ± SEM.
p value <0.05 between MKR vehicle and MKR alendronate-treated groups.